These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 33792199)

  • 1. Do SGLT-2 inhibitors exhibit similar cardiovascular benefit in patients with heart failure with reduced or preserved ejection fraction?
    Singh AK; Singh R; Misra A
    J Diabetes; 2021 Jul; 13(7):596-600. PubMed ID: 33792199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Singh AK; Singh R
    Diabetes Metab Syndr; 2021; 15(1):351-359. PubMed ID: 33503584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do SGLT-2 inhibitors exhibit similar cardiovascular benefit in patients having reduced ejection fraction heart failure with type 2 diabetes, prediabetes and normoglycemia?
    Singh AK; Singh R
    Diabetes Metab Syndr; 2021; 15(6):102282. PubMed ID: 34562869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?
    Al Rifai M; Newby LK; Nair AP; Misra A; Rogers JG; Fedson S; Virani SS
    Curr Atheroscler Rep; 2022 Aug; 24(8):627-634. PubMed ID: 35653033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis.
    Razuk V; Chiarito M; Cao D; Nicolas J; Pivato CA; Camaj A; Power D; Beerkens F; Jones D; Alter A; Mathew A; Spirito A; Contreras JP; Dangas GD; Mehran R
    Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(6):557-567. PubMed ID: 35021205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of sodium-glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta-analysis of randomized controlled trials.
    Zheng C; Lin M; Chen Y; Xu H; Yan L; Dai H
    Cardiovasc Diabetol; 2021 Apr; 20(1):83. PubMed ID: 33888126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trials.
    Lu Y; Li F; Fan Y; Yang Y; Chen M; Xi J
    Eur J Intern Med; 2021 May; 87():20-28. PubMed ID: 33824055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials.
    Vaduganathan M; Docherty KF; Claggett BL; Jhund PS; de Boer RA; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Desai AS; McMurray JJV; Solomon SD
    Lancet; 2022 Sep; 400(10354):757-767. PubMed ID: 36041474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure.
    Kasperova BJ; Mraz M; Svoboda P; Hlavacek D; Kratochvilova H; Modos I; Vrzackova N; Ivak P; Janovska P; Kobets T; Mahrik J; Riecan M; Steiner Mrazova L; Stranecky V; Netuka I; Cajka T; Kuda O; Melenovsky V; Stemberkova Hubackova S; Haluzik M
    Cardiovasc Diabetol; 2024 Jun; 23(1):223. PubMed ID: 38943140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX; Liang S; Gao L; Liu H
    PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and design of the Biventricular Evaluation of Gliflozins effects In chroNic Heart Failure: BEGIN-HF study.
    Correale M; Antohi EL; Inciardi RM; Mazzeo P; Coiro S; Ishihara S; Petroni R; Monitillo F; Leone M; Triggiani M; Sarwar CMS; Dungen HD; Talha KM; Brunetti ND; Butler J; Nodari S;
    ESC Heart Fail; 2023 Jun; 10(3):2066-2073. PubMed ID: 36924023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of background insulin therapy on cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes: A meta-analysis of cardiovascular outcome trials.
    Singh AK; Singh R
    Diabetes Res Clin Pract; 2021 Feb; 172():108648. PubMed ID: 33421444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
    Kosiborod M; Lam CSP; Kohsaka S; Kim DJ; Karasik A; Shaw J; Tangri N; Goh SY; Thuresson M; Chen H; Surmont F; Hammar N; Fenici P;
    J Am Coll Cardiol; 2018 Jun; 71(23):2628-2639. PubMed ID: 29540325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A protocol for meta-analysis.
    Fukuta H; Hagiwara H; Kamiya T
    Medicine (Baltimore); 2021 Dec; 100(51):e28448. PubMed ID: 34941199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure.
    Nassif ME; Kosiborod M
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2():19-23. PubMed ID: 31081589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT-2 Inhibitor Use in Heart Failure: A Review for Nurses.
    March KL; Lukas JG; Berei TJ; Shah SP; Cave BE
    Crit Care Nurs Q; 2022 Apr-Jun 01; 45(2):189-198. PubMed ID: 35212658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
    Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
    Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure.
    Butler J; Handelsman Y; Bakris G; Verma S
    Eur J Heart Fail; 2020 Apr; 22(4):604-617. PubMed ID: 31926059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit of sodium-glucose cotransporter-2 inhibitors on survival outcome is related to the type of heart failure: A meta-analysis.
    Zhao L; Guo W; Huang W; Wang L; Huang S
    Diabetes Res Clin Pract; 2022 May; 187():109871. PubMed ID: 35413392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do background ischemic heart disease and baseline left ventricular ejection fraction affect cardiovascular efficacy of SGLT-2 inhibitors in heart failure with reduced ejection fraction?
    Patoulias D; Papadopoulos C; Kassimis G; Doumas M
    J Cardiovasc Med (Hagerstown); 2022 Jan; 23(1):e30-e32. PubMed ID: 34570038
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.